Over the past three decades, synthetic antibody repertoires have advanced significantly, aiding the development of novel therapeutic and diagnostic antibodies. Currently, at least six antibodies derived from such repertoires are in clinical use, with hundreds more in clinical trials. Most repertoires contain billions of unique antibodies, generated by recombining fragments of known human antibodies. However, these repertoires often yield antibodies with low stability and a high tendency for polyreactivity (tendency to bind to unwanted targets), complicating the costly development process.